A Combination of Blood Lymphocytes and AST Levels Distinguishes Patients with Small Hepatocellular Carcinomas from Non-cancer Patients

Basit Öğe Kaydı
dc.authoridÖĞÜT, ZEKİ/0000-0002-7698-9586
dc.authoridGozukara Bag, Harika Gozde/0000-0003-1208-4072
dc.authoridAkbulut, Sami/0000-0002-6864-7711
dc.authoridince, volkan/0000-0002-0714-490X
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridCarr, Brian/0000-0002-6111-5077
dc.authoridTuncer, Adem/0000-0001-5381-513X
dc.authorwosidÖĞÜT, ZEKİ/IZP-6632-2023
dc.authorwosidGozukara Bag, Harika Gozde/ABG-7588-2020
dc.authorwosidAkbulut, Sami/L-9568-2014
dc.authorwosidince, volkan/M-7325-2017
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.contributor.authorCarr, Brian, I
dc.contributor.authorBag, Harika Gozukara
dc.contributor.authorInce, Volkan
dc.contributor.authorAkbulut, Sami
dc.contributor.authorErsan, Veysel
dc.contributor.authorUsta, Sertac
dc.contributor.authorIsik, Burak
dc.date.accessioned2024-08-04T20:50:51Z
dc.date.available2024-08-04T20:50:51Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose HCC patients typically present at an advanced tumor stage, in which surgical therapies cannot be used. Screening ultrasound exams can increase the numbers of patients diagnosed with small tumors, but are often not used in patients at risk for HCC. We evaluated clinically available and cheap potential blood tests as biomarkers for screening patients at risk for HCC. Methods A comparison was made of commonly used blood count and liver function parameters in a group of patients (n = 101) with small HCCs (<= 3 cm) or without HCC (n = 275), who presented for liver transplantation in our institute. Results Significant differences were found for blood lymphocytes and AST levels. This 2-parameter combination was found to be significantly different between patients with small HCCs versus no HCC. Using the combination of lymphocytes and AST levels to dichotomize the HCC patients, only blood levels of alpha-fetoprotein among the tumor characteristics were found to be significantly different among the 2 HCC groups, as well as levels of blood total bilirubin, ALKP, and PLR ratio. The results were confirmed using a separate smaller cohort of non-transplanted small size HCC patients. Conclusion The combination of elevated blood levels of lymphocyte counts and AST levels holds promise for screening of patients with chronic liver disease who are at risk for HCC.en_US
dc.description.sponsorshipNIH [CA 82723]en_US
dc.description.sponsorshipThis work was supported in part by NIH grant CA 82723 (B.I.C).en_US
dc.identifier.doi10.1007/s12029-021-00740-9
dc.identifier.endpage1216en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue4en_US
dc.identifier.pmid34762264en_US
dc.identifier.scopus2-s2.0-85118853888en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1211en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-021-00740-9
dc.identifier.urihttps://hdl.handle.net/11616/100302
dc.identifier.volume52en_US
dc.identifier.wosWOS:000717385700003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLiver transplantationen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectLymphocyteen_US
dc.subjectASTen_US
dc.subjectBiomarkersen_US
dc.titleA Combination of Blood Lymphocytes and AST Levels Distinguishes Patients with Small Hepatocellular Carcinomas from Non-cancer Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu